Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
暂无分享,去创建一个
Martin C. Müller | H. Heimpel | H. Einsele | J. Hasford | K. Spiekermann | M. Pfreundschuh | L. Kanz | S. Schnittger | C. Haferlach | D. Hossfeld | G. Ehninger | D. Heim | C. Waller | M. Kneba | R. Hehlmann | A. Fabarius | A. Neubauer | A. Hochhaus | S. Krause | C. Nerl | G. Baerlocher | B. Hanfstein | H. Kolb | S. Saussele | F. Stegelmann | M. Lauseker | M. Pfirrmann | U. Proetel | J. Dengler | C. Falge | Nadine Pletsch | Annette Schreiber